Press Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

https://ift.tt/RnGcMUB

Sarclisa^® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

from Sanofi - Aventis Groupe https://ift.tt/wvpqhNI
via IFTTT

" May good health envelop you, spurring a quick recovery. .. "

from health care https://ift.tt/782Th3z
via IFTTT https://ift.tt/6JnfAT4